One in four abortions in the U.S. rely on telehealth access to mifepristone, but antiabortion activists want to ban it
May 27, 2026
By Meghan Bartels, edited by Tanya Lewis
After a tense few weeks during which U.S. courts twice revoked and reinstated telehealth access to the abortion pill mifepristone, the drug remains available without an in-office appointment—for now. But doctors and policy experts worry that uncertainty and any future rollback in access will make things harder for people seeking to end a pregnancy and place added pressure on the health care system.
Since 2022, when the Supreme Court’s ruling in Dobbs v. Jackson Women’s Health Organization overturned the right to abortion enshrined in Roe v. Wade, antiabortion proponents have focused on mifepristone. They claim, despite a wealth of evidence to the contrary, that the drug is unsafe. First approved in the U.S. in 2000, mifepristone is currently used here in combination with the drug misoprostol up to 10 weeks into a pregnancy.